Sable Bio

Investor: MMC Ventures

Sable Bio, a London-based AI drug safety startup, has successfully raised £2.8 million in seed funding, with MMC Ventures leading the investment round.Summary of transaction details:Value: £2.8 millionSector: Healthcare & Biotech (AI Drug Safety)Advisor: Not mentionedKey Entities: Sable Bio (Target), MMC Ventures (Lead Investor)Location: London, UKNote: This funding will be instrumental in scaling Sable Bio's platform, which aids pharmaceutical companies in identifying safety risks earlier in the drug discovery process, thereby improving efficiency and patient outcomes.